
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Extracell Vesicles</journal-id><journal-id journal-id-type="iso-abbrev">J Extracell Vesicles</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2001-3078</journal-id><journal-id journal-id-type="publisher-id">JEV2</journal-id><journal-title-group><journal-title>Journal of Extracellular Vesicles</journal-title></journal-title-group><issn pub-type="epub">2001-3078</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33391636</article-id><article-id pub-id-type="pmc">7769856</article-id><article-id pub-id-type="doi">10.1002/jev2.12050</article-id><article-id pub-id-type="publisher-id">JEV212050</article-id><article-categories><subj-group subj-group-type="overline"><subject>Short Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Extracellular vesicles containing ACE2 efficiently prevent infection by SARS&#x02010;CoV&#x02010;2 Spike protein&#x02010;containing virus</article-title><alt-title alt-title-type="left-running-head">COCOZZA et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="jev212050-cr-0001" contrib-type="author"><name><surname>Cocozza</surname><given-names>Federico</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4311-3083</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jev212050-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="jev212050-note-0001">
<sup>*</sup>
</xref></contrib><contrib id="jev212050-cr-0002" contrib-type="author"><name><surname>N&#x000e9;vo</surname><given-names>Nathalie</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6350-7122</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jev212050-note-0001">
<sup>*</sup>
</xref></contrib><contrib id="jev212050-cr-0003" contrib-type="author"><name><surname>Piovesana</surname><given-names>Ester</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4983-7819</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jev212050-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="jev212050-note-0001">
<sup>*</sup>
</xref></contrib><contrib id="jev212050-cr-0004" contrib-type="author"><name><surname>Lahaye</surname><given-names>Xavier</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7124-1707</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jev212050-cr-0005" contrib-type="author"><name><surname>Buchrieser</surname><given-names>Julian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4790-7577</contrib-id><xref ref-type="aff" rid="jev212050-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jev212050-cr-0006" contrib-type="author"><name><surname>Schwartz</surname><given-names>Olivier</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0729-1475</contrib-id><xref ref-type="aff" rid="jev212050-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jev212050-cr-0007" contrib-type="author"><name><surname>Manel</surname><given-names>Nicolas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1481-4430</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jev212050-cr-0008" contrib-type="author" corresp="yes"><name><surname>Tkach</surname><given-names>Mercedes</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8011-9444</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jev212050-note-0002">
<sup>&#x02020;</sup>
</xref><address><email>mercedes.tkach@curie.fr</email></address></contrib><contrib id="jev212050-cr-0009" contrib-type="author" corresp="yes"><name><surname>Th&#x000e9;ry</surname><given-names>Clotilde</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8294-6884</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jev212050-note-0002">
<sup>&#x02020;</sup>
</xref><address><email>clotilde.thery@curie.fr</email></address></contrib><contrib id="jev212050-cr-0010" contrib-type="author" corresp="yes"><name><surname>Martin&#x02010;Jaular</surname><given-names>Lorena</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1511-8576</contrib-id><xref ref-type="aff" rid="jev212050-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jev212050-note-0002">
<sup>&#x02020;</sup>
</xref><address><email>lorena.martin-jaular@curie.fr</email></address></contrib></contrib-group><aff id="jev212050-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">INSERM U932</named-content>
<named-content content-type="organisation-division">Institut Curie Centre de Recherche</named-content>
<institution>PSL Research University</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="jev212050-aff-0002">
<label><sup>2</sup></label>
<institution>Universit&#x000e9; de Paris</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="jev212050-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Virus and Immunity Unit</named-content>
<institution>Institut Pasteur and CNRS UMR 3569</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Mercedes Tkach, INSERM U932, Institut Curie Centre de Recherche, PSL Research University, Paris 75005, France<break/>Email: <email>mercedes.tkach@curie.fr</email><break/>Clotilde Th&#x000e9;ry, INSERM U932, Institut Curie Centre de Recherche, PSL Research University, Paris 75005, France<break/>Email: <email>clotilde.thery@curie.fr</email><break/>Lorena Martin&#x02010;Jaular, INSERM U932, Institut Curie Centre de Recherche, PSL Research University, Paris 75005, France<break/>Email: <email>lorena.martin-jaular@curie.fr</email><break/></corresp><fn id="jev212050-note-0001"><label>*</label><p>Federico Cocozza, Nathalie N&#x000e9;vo, and Ester Piovesana are co&#x02010;first authors.</p></fn><fn id="jev212050-note-0002"><label>&#x02020;</label><p>Mercedes Tkach, Clotilde Th&#x000e9;ry, and Lorena Martin&#x02010;Jaular are co&#x02010;last authors.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/jev2.v10.2</issue-id><elocation-id>e12050</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>16</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright">&#x000a9; 2020 International Society for Extracellular Vesicles<copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 The Authors. <italic>Journal of Extracellular Vesicles</italic> published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JEV2-10-e12050.pdf"/><abstract><title>Abstract</title><p>SARS&#x02010;CoV&#x02010;2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by host TMPRSS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2&#x02010;EVs are efficient decoys for SARS&#x02010;CoV&#x02010;2 S protein&#x02010;containing lentivirus. Reduction of infectivity positively correlates with the level of ACE2, is much more efficient than with soluble ACE2 and further enhanced by the inclusion of TMPRSS2.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jev212050-kwd-0001">ACE2</kwd><kwd id="jev212050-kwd-0002">EV therapy</kwd><kwd id="jev212050-kwd-0003">SARS&#x02010;CoV&#x02010;2</kwd><kwd id="jev212050-kwd-0004">TMPRSS2</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Institut Curie, INSERM, CNRS</funding-source></award-group><award-group id="funding-0002"><funding-source>H2020&#x02010;MSCA&#x02010;ITN</funding-source><award-id>722148</award-id><award-id>TRAIN&#x02010;EV</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>ARC </institution><institution-id institution-id-type="open-funder-registry">10.13039/100007391</institution-id></institution-wrap></funding-source><award-id>RF20180206962</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>INCA </institution><institution-id institution-id-type="open-funder-registry">10.13039/100013501</institution-id></institution-wrap></funding-source><award-id>11548</award-id></award-group><award-group id="funding-0005"><funding-source>LABEX DCBIOL</funding-source><award-id>ANR&#x02010;10&#x02010;IDEX&#x02010;0001&#x02010;02 PSL*</award-id><award-id>ANR&#x02010;11&#x02010;LABX&#x02010;0043</award-id></award-group><award-group id="funding-0006"><funding-source>LABEX VRI</funding-source><award-id>ANR&#x02010;10&#x02010;LABX&#x02010;77</award-id></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>ANRS </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003323</institution-id></institution-wrap></funding-source><award-id>ECTZ36691</award-id><award-id>ECTZ71745</award-id></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>Sidaction </institution><institution-id institution-id-type="open-funder-registry">10.13039/100009060</institution-id></institution-wrap></funding-source><award-id>17&#x02010;1&#x02010;AAE&#x02010;11097&#x02010;2</award-id></award-group><award-group id="funding-0009"><funding-source><institution-wrap><institution>ANR </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001665</institution-id></institution-wrap></funding-source><award-id>ANR&#x02010;19&#x02010;CE15&#x02010;0018&#x02010;01</award-id><award-id>ANR&#x02010;18&#x02010;CE92&#x02010;0022&#x02010;01</award-id></award-group><award-group id="funding-0010"><funding-source>DIM1HEALTH</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="8"/><word-count count="4997"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.6 mode:remove_FC converted:28.12.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jev212050-cit-0025">
<string-name>
<surname>Cocozza</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>N&#x000e9;vo</surname>
<given-names>N</given-names>
</string-name>,<string-name>
<surname>Piovesana</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al.&#x000a0;<article-title>Extracellular vesicles containing ACE2 efficiently prevent infection by SARS&#x02010;CoV&#x02010;2 Spike protein&#x02010;containing virus</article-title>. <source xml:lang="en">J Extracell Vesicles</source>. <year>2020</year>;<volume>10</volume>:<elocation-id>e12050</elocation-id>
<pub-id pub-id-type="doi">10.1002/jev2.12050</pub-id>
</mixed-citation>
</p></notes></front><body><sec id="jev212050-sec-0010"><label>1</label><title>INTRODUCTION</title><p>SARS&#x02010;CoV&#x02010;2 is the infectious causative agent of the COVID&#x02010;19 pandemic (Zhou et&#x000a0;al., <xref rid="jev212050-bib-0001" ref-type="ref">2020</xref>). Viral entry into host cells is mediated by the interaction of the spike (S) protein on the surface of SARS&#x02010;CoV&#x02010;2 with the surface receptor angiotensin&#x02010;converting enzyme 2 (ACE2) (Walls et&#x000a0;al., <xref rid="jev212050-bib-0002" ref-type="ref">2020</xref>). After binding to ACE2, the S protein is cleaved by Transmembrane protease serine 2 (TMPRSS2) and becomes fusogenic thus allowing viral entry (Hoffmann et&#x000a0;al., <xref rid="jev212050-bib-0003" ref-type="ref">2020</xref>).</p><p>ACE2 is expressed at the surface of pneumocytes and intestinal epithelial cells which are potential target cells for infection (Ziegler et&#x000a0;al., <xref rid="jev212050-bib-0004" ref-type="ref">2020</xref>). A soluble form of the ACE2 ectodomain can be released after cleavage by ADAM10 or ADAM17 in different physiological conditions (Jia et&#x000a0;al., <xref rid="jev212050-bib-0005" ref-type="ref">2009</xref>). In addition, TMPRSS2 can compete with the metalloproteases for ACE2 cleavage (Heurich et&#x000a0;al., <xref rid="jev212050-bib-0006" ref-type="ref">2014</xref>). Soluble recombinant ACE2 neutralizes SARS&#x02010;CoV&#x02010;2 by binding the S protein and has been proven to reduce entry of SARS&#x02010;CoV&#x02010;2 into Vero&#x02010;E6 cells and engineered human organoids (Monteil et&#x000a0;al., <xref rid="jev212050-bib-0007" ref-type="ref">2020</xref>). ACE2, however, is synthesized as a transmembrane protein, like TMPRSS2. We postulate that ACE2 could be present on the surface of extracellular vesicles (EVs), which could result in better efficacy as a decoy to capture SARS&#x02010;CoV&#x02010;2. Furthermore, concomitant presence of an active serine&#x02010;protease TMPRSS2 on the same EVs could further interfere with viral infectivity, by forcing viral fusion on the EV membrane, rather than on target cells.</p><p>EVs are lipid bilayer&#x02010;enclosed structures containing transmembrane proteins, membrane&#x02010;associated proteins, cytosolic proteins and nucleic acids that are released into the environment by different cell types (Mathieu et&#x000a0;al., <xref rid="jev212050-bib-0008" ref-type="ref">2019</xref>). Since EVs have the same membrane orientation as cells, they expose at their surface the extracellular domains of transmembrane proteins that can bind to nearby or long&#x02010;distance targets. By specifically binding to different proteins and protein&#x02010;containing structures, EVs can act as a decoy for virus (De Carvalho et&#x000a0;al., <xref rid="jev212050-bib-0009" ref-type="ref">2014</xref>) and bacterial toxins (Keller et&#x000a0;al., <xref rid="jev212050-bib-0010" ref-type="ref">2020</xref>), thus suggesting a potential role as therapeutic agents.</p></sec><sec id="jev212050-sec-0020"><label>2</label><title>RESULTS</title><p>In order to explore the hypothesis that EVs can be used as SARS&#x02010;CoV&#x02010;2 decoy agents, we first assessed whether ACE2 can be present in EVs from cell lines derived from tissues expressing ACE2. As cell lines endogenously expressing ACE2, we used the human lung epithelial cell line Calu&#x02010;3 and the epithelial colorectal cell line Caco&#x02010;2 which are known targets for SARS&#x02010;CoV&#x02010;2 infection (Hoffmann et&#x000a0;al., <xref rid="jev212050-bib-0003" ref-type="ref">2020</xref>). In a pilot experiment, Calu&#x02010;3 and Caco&#x02010;2 were cultured in medium without fetal bovine serum (FBS) for 24&#x000a0;h and EVs were isolated from the cell conditioned medium (CCM) by size&#x02010;exclusion chromatography (SEC). This technique allows the separation of EVs from soluble proteins (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1a</xref>). We analysed side&#x02010;by&#x02010;side fractions enriched in EVs (pooled fractions 7&#x02013;11), in soluble factors (pooled fractions 17&#x02013;21), and the fractions in&#x02010;between (pooled fraction 12&#x02013;16) (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1a</xref>). Particle quantification by nanoparticle tracking analysis (NTA) confirmed that the majority of particles released by Calu&#x02010;3 and Caco&#x02010;2 cells were isolated in EV&#x02010;containing fractions (Supplementary Figure A). In this experiment, Caco&#x02010;2 cells released less EVs but of similar mode size than Calu&#x02010;3 (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1b</xref>). These EVs contained ACE2 protein as well as known EV markers (CD63, CD81 ADAM10) (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1c</xref>). In addition, although Caco&#x02010;2 and Calu&#x02010;3 expressed TMPRSS2, this protease was not released in EVs (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1c</xref>). To obtain EVs with high amounts of ACE2 and TMPRSS2 to be tested as decoy agents, we switched to 293FT cells that could be easily genetically&#x02010;edited. We transduced 293FT cells with lentivirus containing ACE2 alone (293FT&#x02010;ACE2) or in combination with TMPRSS2 (293FT&#x02010;ACE2&#x02010;TMPRSS2). 293FT cells transduced with lentivirus containing empty plasmids were used as a control (293FT&#x02010;mock). The three 293FT cell lines were cultured in FBS&#x02010;containing EV&#x02010;depleted medium and EVs were isolated from concentrated CCM by SEC. We observed a high count of particles with comparable mode sizes in EV fractions from all 293FT cell lines (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1d</xref>, Supplementary Figure A) coincident with the presence of CD63, CD81, ADAM10 and HSP70 EV markers (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1e</xref>). Overexpression of ACE2 in 293FT cells led to the incorporation of this molecule into EVs (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1e</xref>) with higher levels found on EVs from 293FT&#x02010;ACE2 than from 293FT&#x02010;ACE2&#x02010;TMPRSS2 (Supplementary Figure B). 293FT&#x02010;mock and 293FT&#x02010;ACE2 cells expressed TMPRSS2, but the predicted full&#x02010;length 54&#x000a0;kDa form was not detected in their EVs: a 30&#x000a0;kDa N&#x02010;terminal fragment devoid of the serine protease domain (Zmora et&#x000a0;al., <xref rid="jev212050-bib-0011" ref-type="ref">2015</xref>) was mainly detected, together with a low level of the glycosylated full&#x02010;length 70&#x000a0;kDa form. Importantly, EVs from 293FT cells overexpressing TMPRSS2 contained higher levels of the full&#x02010;length TMPRSS2 protein and less of a cleaved form than EVs from 293FT&#x02010;mock or 293FT&#x02010;ACE2 cells (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1e</xref>, Supplementary Figure C) (Afar et&#x000a0;al., <xref rid="jev212050-bib-0012" ref-type="ref">2001</xref>). Since the ACE2 ectodomain can be released after cleavage (Jia et&#x000a0;al., <xref rid="jev212050-bib-0005" ref-type="ref">2009</xref>), we evaluated whether cells overexpressing ACE2 release soluble ACE2 in addition to EV&#x02010;associated ACE2. To do this, we analysed the presence of ACE2, the EV marker CD81 and the non&#x02010;EVs component AChE (Liao et&#x000a0;al., <xref rid="jev212050-bib-0013" ref-type="ref">2019</xref>) by WB on EV fractions (1&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup> &#x000a0; particles) and the intermediate and soluble fractions obtained from the same amount of CCM. We detected some particles in intermediate and soluble fractions from the three 293FT cell lines, that probably came from the depleted medium since they did not contain EV markers by WB (Supplementary Figure A, D, E). AChE was enriched in soluble fractions whereas CD81 was mainly found in EV fractions validating our isolation protocol for EVs and soluble components (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1f</xref>). Importantly, ACE2 was found as a full&#x02010;length transmembrane form in the EV fractions, as two shorter cleaved forms in the soluble fractions, and a mixture of all forms in the intermediate fractions (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1f</xref>). Intermediate fractions thus represent a mixture of EVs and soluble proteins and for this reason were not further analysed. Low levels of ACE2 were found in the soluble SEC fractions of 293FT&#x02010;ACE2 cells when compared to the levels present on the EV&#x02010;containing fraction (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1f</xref>, <xref rid="jev212050-fig-0001" ref-type="fig">1g</xref>). By contrast, 293FT&#x02010;ACE2&#x02010;TMPRSS2 cells released similar amounts of EV&#x02010;associated as of soluble ACE2 (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1f,1g</xref>), suggesting that the overexpression of the protease cleaves ACE2 as previously described (Heurich et&#x000a0;al., <xref rid="jev212050-bib-0006" ref-type="ref">2014</xref>), favouring its secretion to the extracellular space as a soluble protein instead of associated to EVs.</p><fig fig-type="FIGURE" xml:lang="en" id="jev212050-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>Isolation and characterization of EVs containing ACE2 and TMPRSS2. (a) Scheme of EV isolation and separation from soluble components by SEC. (b) NTA quantification and mode size of the particles in EV&#x02010;containing SEC fractions obtained from Caco&#x02010;2 and Calu&#x02010;3 cells. (c) WB analysis of ACE2, TMPRSS2 and different EV markers in lysates from 4&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>&#x000a0; cells and 1&#x000a0;&#x000d7;&#x000a0;10<sup>10</sup> &#x000a0;<xref rid="jev212050-bib-0010" ref-type="ref">2020</xref> (Caco&#x02010;2) or 0.5&#x000a0;&#x000d7;&#x000a0;10<sup>10</sup>&#x000a0;<xref rid="jev212050-bib-0010" ref-type="ref">2020</xref> (Calu&#x02010;3) particles obtained from EV SEC fractions. One experiment. (d) NTA quantification and mode size of the particles in EV&#x02010;containing fractions obtained from 293FT&#x02010;mock, 293FT&#x02010;ACE2 and 293FT&#x02010;ACE2&#x02010;TMPRSS2 cell lines. Different symbols correspond to independent experiments. Error bars indicate SEM. (e) WB analysis of ACE2, TMPRSS2 and different EV markers in lysates from 4&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>&#x000a0;cells and 1&#x000a0;&#x000d7;&#x000a0;10<sup>10</sup>&#x000a0;<xref rid="jev212050-bib-0010" ref-type="ref">2020</xref> particles from EV SEC fractions obtained from the three 293FT cell lines. (f&#x02010;g) WB analysis of ACE2, CD81 and AChE on EV, intermediate and soluble fractions from the three 293FT cell lines. 1&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>&#x000a0; particles from the EV fraction or material recovered from the same corresponding volume of CCM, for the intermediate or soluble fractions, were loaded on the gel. (f) Representative WB. (g) Quantification of ACE2 signal (pooled full&#x02010;length and cleaved forms) in 2&#x02013;3 independent WB</p></caption><graphic id="nlm-graphic-1" xlink:href="JEV2-10-e12050-g001"/></fig><p>We then analysed the capacity of ACE2&#x02010; and ACE2&#x02010;TMPRSS2&#x02010;containing EVs to reduce the infection of target cells by a lentivirus containing SARS&#x02010;CoV&#x02010;2&#x02010;S protein. The virus used in this study was produced using an HIV packaging vector pseudotyped with SARS&#x02010;CoV&#x02010;2 Spike protein and including a GFP&#x02010;coding sequence, which is expressed in infected cells. A variant of SARS&#x02010;CoV&#x02010;2 Spike protein bearing a region of the tail of the HIV gp41, instead of the Spike tail, previously shown to enhance infection of pseudotyped virus (Moore et&#x000a0;al., <xref rid="jev212050-bib-0014" ref-type="ref">2004</xref>) was used. First, we determined the infectivity of the target cells Caco&#x02010;2, Calu&#x02010;3 and 293FT&#x02010;ACE2 by SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped lentivirus and observed that each of these cell lines is infected similarly in a concentration&#x02010;dependent manner (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2a</xref>). To assess the ability of ACE2&#x02010;containing EVs to decrease virus infectivity <italic>in vitro</italic>, we infected target cells with SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped virus in the presence or the absence of EVs isolated from 293FT&#x02010;mock (mock&#x02010;EVs) or 293FT&#x02010;ACE2 (ACE2&#x02010;EVs) or 293FT&#x02010;ACE2&#x02010;TMPRSS2 cells (ACE2&#x02010;TMPRSS2&#x02010;EVs) (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2b</xref>). Infection of 293FT&#x02010;ACE2 cells in the presence of ACE2&#x02010;EVs and ACE2&#x02010;TMPRSS2&#x02010;EVs was reduced while infection remained unaffected by mock&#x02010;EVs (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2c</xref> and quantification in 2d). Importantly, this inhibition was dependent on the dose of EVs (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2d</xref>). Caco&#x02010;2 infection was also reduced in the presence of ACE2&#x02010;EVs and ACE2&#x02010;TMPRSS2&#x02010;EVs (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2e</xref>). We then quantified by enzyme&#x02010;linked immunosorbent assay (ELISA) the amount of ACE2 released by these cell lines. As previously documented by western blot (Figure&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1f</xref> and&#x000a0;<xref rid="jev212050-fig-0001" ref-type="fig">1g</xref>), we observed that 293FT&#x02010;ACE2 cells released high levels of ACE2 mainly associated with EVs while 293FT&#x02010;ACE2&#x02010;TMPRSS2 cells released lower ACE2 levels that were equally distributed between EV and soluble fractions (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2f</xref>). Strikingly, ACE2 in the soluble fractions from these latter cells could not inhibit SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped virus infection as compared to a comparable amount of ACE2 associated with EVs (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2g</xref>). When re&#x02010;plotting the results obtained in Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2d</xref> as a function of the absolute amount of ACE2 measured for these same samples by ELISA (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2f</xref>), we observed that EVs from cells overexpressing the full length TMPRSS2 together with ACE2 were more efficient at inhibiting SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped viral infection than those from cells overexpressing ACE2 alone (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2h</xref>). Moreover, to achieve similar levels of inhibition of lentiviral infection as those observed with ACE2&#x02010; or ACE2&#x02010;TMPRSS2&#x02010;EVs, 500 to 1500 times more of the soluble recombinant human ACE2 had to be used (Figure&#x000a0;<xref rid="jev212050-fig-0002" ref-type="fig">2h</xref>) in accordance with previous publications (Monteil et&#x000a0;al., <xref rid="jev212050-bib-0007" ref-type="ref">2020</xref>). Altogether, these findings highlight the increased efficiency of EVs containing full&#x02010;length ACE2 to inhibit SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped viral entry when compared to the soluble protein alone. The enhanced efficiency of EVs from cells overexpressing TMPRSS2 could be due to the presence of TMPRSS2 together with ACE2, leading to fusion of the virus with the EV thus impairing their capacity to infect cells, and/or to other modifications of the EV composition induced by overexpression of TMPRSS2 in the EV&#x02010;secreting cells.</p><fig fig-type="FIGURE" xml:lang="en" id="jev212050-fig-0002" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Inhibition of SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped virus infection with ACE2 EVs. (a) Infection of 293FT&#x02010;ACE2, Caco&#x02010;2 and Calu&#x02010;3 cells with different dilutions of a SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped lentivirus encoding for eGFP. The number of infected cells was calculated by multiplying the percentage of GFP&#x02010;positive cells by the initial number of cells. (b) Scheme of the infectivity assay with different treatments. (c) Dot plots showing the percentage of infected (=&#x000a0;eGFP+) 293FT&#x02010;ACE2 cells obtained after incubation with viruses alone (0.05 dilution), in combination with 1&#x000a0;&#x000d7;&#x000a0;10<sup>10</sup>&#x000a0;<xref rid="jev212050-bib-0010" ref-type="ref">2020</xref> EVs from the different 293FT cell lines or in combination with rACE2 (25 &#x003bc;g/ml). This rACE2 level represents 250 and 2960 times more ACE2 than the one contained in ACE2&#x02010;EVs and ACE2&#x02010;TMPRSS2&#x02010;EVs, respectively, measured by ELISA. (d) Quantification of the number of infected 293FT&#x02010;ACE2 cells in the presence of EVs. The percentage of eGFP+ cells was measured by FACS and normalized to infection with the virus alone (100%). Results from three independent experiments are shown. All replicates from each experiment are included. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 (Dunnett's test). (e) Caco&#x02010;2 infection in the presence of ACE2&#x02010;EVs and ACE2&#x02010;TMPRSS2&#x02010;EVs. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 (Dunnett's test). (f) ACE2 quantification by ELISA in EV and soluble fractions obtained from the three different 293FT cell lines. Results are expressed as ng per million of secreting cells. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 (non&#x02010;parametric ANOVA with Kruskal&#x02010;Wallis test for comparison among all groups). ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 (Mann&#x02010;Whitney test for comparison among EV vs soluble for each cell line). (g) Comparison of the effect on 293T&#x02010;ACE2 infection of 1&#x000a0;&#x000d7;&#x000a0;10<sup>10</sup>&#x000a0;<xref rid="jev212050-bib-0010" ref-type="ref">2020</xref> EVs and soluble fractions from an equivalent volume of CCM of 293FT&#x02010;ACE2&#x02010;TMPRSS2 cells. **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 (t&#x02010;test) (h) Percentage of infectivity from Figure <xref rid="jev212050-fig-0002" ref-type="fig">2d</xref> related to the amount of EV&#x02010;associated ACE2, quantified by ELISA in Figure <xref rid="jev212050-fig-0002" ref-type="fig">2f</xref>. As a comparison, cell infection rates in the presence of increasing amount of recombinant ACE2 (rACE2) were also determined (n&#x000a0;=&#x000a0;4). Lines represent results of linear regression analysis. Comparison of slopes and intercepts using Prism indicated that the three regression lines are distinct but parallels. ACE2&#x02010;TMPRSS2 is different from ACE2 (<italic>P</italic>&#x000a0;=&#x000a0;0.0017) and rACE2 is different from ACE2&#x02010;TMPRSS2 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and from ACE2 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001)</p></caption><graphic id="nlm-graphic-3" xlink:href="JEV2-10-e12050-g002"/></fig></sec><sec id="jev212050-sec-0030"><label>3</label><title>DISCUSSION</title><p>Our data demonstrate that EVs containing ACE2, alone or in combination with TMPRSS2, block SARS&#x02010;CoV&#x02010;2 Spike&#x02010;dependent infection in a much more efficient manner than soluble ACE2. Thus, ACE2&#x02010;EVs represent a potential versatile therapeutic tool to block not only SARS&#x02010;CoV&#x02010;2 infection but also other coronavirus infections that use the ACE2 receptor for host cell entry, such as SARS&#x02010;CoV (Li et&#x000a0;al., <xref rid="jev212050-bib-0015" ref-type="ref">2003</xref>) and NL63 (H et&#x000a0;al., <xref rid="jev212050-bib-0016" ref-type="ref">2005</xref>). Further studies to determine the efficacy of the ACE2/TMPRSS2&#x02010;EVs in experimental models of SARS&#x02010;CoV&#x02010;2 virus need to be conducted to validate their therapeutic use for COVID&#x02010;19, but also the lack of side&#x02010;effects. The use of engineered EVs as therapeutic agents has been proposed several years ago and is currently being explored in humans (Wiklander et&#x000a0;al., <xref rid="jev212050-bib-0017" ref-type="ref">2019</xref>), suggesting that well&#x02010;designed EV therapeutics against COVID&#x02010;19 may be feasible to prevent initial infection or further internal dissemination of the virus, and thus reducing the virus burden and disease severity. However, as recently highlighted by the International Societies for EV (ISEV) and for Cellular Therapies (ISCT) (B&#x000f6;rger et&#x000a0;al., <xref rid="jev212050-bib-0018" ref-type="ref">2020</xref>), despite the urgency induced by the current pandemic, EV&#x02010;based therapeutic developments for COVID&#x02010;19 will have to meet as strong criteria of manufacturing processes, quality controls and compliance to safety regulation as any other therapies, before they can be implemented in human subjects.</p><p>Note: a speculative article discussing the idea that we demonstrate experimentally here was published while we were preparing this article, thus showing concomitant emergence of similar scientific ideas (Inal, <xref rid="jev212050-bib-0019" ref-type="ref">2020</xref>).</p></sec><sec id="jev212050-sec-0040"><label>4</label><title>METHODS</title><sec id="jev212050-sec-0050"><label>4.1</label><title>Cells</title><p>Human Caco&#x02010;2 (HTB&#x02010;37) and Calu&#x02010;3 (HTB&#x02010;55) were purchased from ATCC and maintained at 37&#x000b0;C in a humidified atmosphere with 5% CO<sub>2</sub>. Caco&#x02010;2 and Calu&#x02010;3 cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (Gibco), 100 U/ml penicillin&#x02010;streptomycin (Thermo Fisher Scientific) and 1% non&#x02010;essential amino acids (Thermo Fisher Scientific). For Calu&#x02010;3 cells the medium was also supplemented with 1&#x000a0;mM sodium pyruvate (Thermo Fisher Scientific) and 10&#x000a0;mM HEPES (Thermo Fisher Scientific). 293FT cells were cultured in DMEM medium (Thermo Fisher Scientific) supplemented with 10% FBS (Eurobio) and 100 U/ml penicillin&#x02010;streptomycin (Thermo Fisher Scientific). 293FT&#x02010;mock, 293FT&#x02010;ACE2 and 293FT&#x02010;ACE2&#x02010;TMPRSS2 cells were generated by stable double transduction with pTRIP&#x02010;SFFV&#x02010;tagBFP&#x02010;2A and pTRIP&#x02010;SFFV&#x02010;TagRFP657&#x02010;2A, pTRIP&#x02010;SFFV&#x02010;tagBFP&#x02010;2A&#x02010;hACE2 and pTRIP&#x02010;SFFV&#x02010;TagRFP657&#x02010;2A, or pTRIP&#x02010;SFFV&#x02010;tagBFP&#x02010;2A&#x02010;hACE2 and pTRIP&#x02010;SFFV&#x02010;TagRFP657&#x02010;2A&#x02010;TMPRSS2, respectively.</p></sec><sec id="jev212050-sec-0060"><label>4.2</label><title>Plasmids</title><p>The plasmids psPAX2, CMV&#x02010;VSVG, pTRIP&#x02010;SFFV&#x02013;tagBFP&#x02010;2A (Cerboni et&#x000a0;al., <xref rid="jev212050-bib-0020" ref-type="ref">2017</xref>) and pTRIP&#x02010;SFFV&#x02010;eGFP&#x02010;NLS (Raab et&#x000a0;al., <xref rid="jev212050-bib-0021" ref-type="ref">2016</xref>) were previously described. pTRIP&#x02010;SFFV&#x02010;TagRFP657&#x02010;2A was generated by PCR from a synthetic gene coding for TagRFP657. pTRIP&#x02010;SFFV&#x02010;tagBFP&#x02010;2A&#x02010;hACE2 and pTRIP&#x02010;SFFV&#x02010;TagRFP657&#x02010;2A&#x02010;TMPRSS2 constructs were obtained by PCR from pLenti6&#x02010;hACE2&#x02010;BSD (hACE2 sequence from Addgene #1786 subcloned into pLenti6&#x02010;BSD) and pCSDest&#x02010;TMPRSS2 (Addgene #53887) respectively. A codon optimized version of the SARS&#x02010;CoV&#x02010;2 S gene (GenBank: QHD43416.1) was transferred into the phCMV backbone (GenBank: AJ318514), by replacing the VSV&#x02010;G gene (phCMV&#x02010;SARS&#x02010;CoV&#x02010;2&#x02010;Spike) (Grzelak et&#x000a0;al., <xref rid="jev212050-bib-0022" ref-type="ref">2020</xref>). phCMV&#x02010;SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;H2 was obtained by PCR from phCMV&#x02010;SARS&#x02010;CoV&#x02010;2&#x02010;Spike in order to include the membrane&#x02010;proximal region of the cytoplasmic domain of HIV&#x02010;1 gp160 (NRVRQGYS, amino acid sequence) (Mammano et&#x000a0;al., <xref rid="jev212050-bib-0023" ref-type="ref">1995</xref>) after residue 1246 of the S protein (Moore et&#x000a0;al., <xref rid="jev212050-bib-0014" ref-type="ref">2004</xref>).</p></sec><sec id="jev212050-sec-0070"><label>4.3</label><title>Preparation of EV&#x02010;depleted medium</title><p>EV&#x02010;depleted medium was obtained by overnight ultracentrifugation of DMEM supplemented with 20% FBS at 100,000 x <italic>g</italic> in a Type 45 Ti rotor (Beckman Coulter, K&#x02010;factor 1042.2). After ultracentrifugation, EV&#x02010;depleted supernatant was carefully pipetted from the top and leaving 7&#x000a0;ml in the bottom. Supernatant was filtered through a 0.22 &#x003bc;m bottle filter (Millipore) and additional DMEM and antibiotics were added to prepare complete medium (10% EV&#x02010;depleted FBS medium).</p></sec><sec id="jev212050-sec-0080"><label>4.4</label><title>EV isolation by size&#x02010;exclusion chromatography</title><p>239FT&#x02010;mock, 293FT&#x02010;ACE2 and 293FT&#x02010;ACE2&#x02010;TMPRSS2 cells were cultured in FBS EV&#x02010;depleted medium for 24 h. Caco&#x02010;2 and Calu&#x02010;3 cells were cultured in FBS&#x02010;free DMEM for 24 h. Cell conditioned medium (CCM) was harvested by pelleting cells at 350xg for 5&#x000a0;min at 4&#x000b0;C three times. Supernatant was centrifuged at 2,000xg for 20&#x000a0;min at 4&#x000b0;C to discard 2K pellet and concentrated on a MiIlipore Filter (MWCO&#x000a0;=&#x000a0;10&#x000a0;kDa, UCF701008) to obtain concentrated CCM. Medium was concentrated to 1&#x000a0;ml from 12 to 41&#x000a0;ml for Caco&#x02010;2 and Calu&#x02010;3 and from 75&#x000a0;ml for 293FT cells and overlaid on a 70&#x000a0;nm qEV size&#x02010;exclusion column (Izon, SP1). 0.5&#x000a0;ml fractions were collected and EVs were recovered in fractions 7 to 11 following manufacturer's instructions. We additionally collected intermediate fractions 12 to 16 and soluble factors in fractions 17 to 21. The three pools of fractions were concentrated using 10&#x000a0;kDa filter (Amicon, UCF801024) to reach a final volume of approximately 100&#x000a0;&#x003bc;l. Samples were stored aliquoted at &#x02010;80&#x000b0;C.</p><p>We have submitted all relevant data of our experiments to the EV&#x02010;TRACK knowledgebase (EV&#x02010;TRACK ID: EV200117) (Van Deun et&#x000a0;al., <xref rid="jev212050-bib-0024" ref-type="ref">2017</xref>).</p></sec><sec id="jev212050-sec-0090"><label>4.5</label><title>Nanoparticle tracking analysis</title><p>NTA was performed to analyse EV fractions, intermediate fractions and soluble fractions using ZetaView PMX&#x02010;120 (Particle Metrix) with software version 8.04.02. The instrument was set a sensitivity 77 and shutter of 70. Measurements were done at 11 different positions (three cycles per position) and frame rate of 30 frames per second.</p></sec><sec id="jev212050-sec-0100"><label>4.6</label><title>Western blotting (WB)</title><p>Cell lysate was prepared using lysis buffer (50&#x000a0;mM Tris, 150&#x000a0;mM NaCl, 1% Triton, pH 8) supplemented with Protease Inhibitor Cocktail (Sigma) at a concentration of 4 &#x000d7; 10<sup>6</sup> &#x000a0; cells in 100 &#x003bc;l of buffer. After incubation for 20&#x000a0;min on ice, samples were centrifuged at 18,500 &#x000d7; <italic>g</italic> for 20&#x000a0;min. The pellet was discarded and the supernatant was kept for further analysis. Cell lysates, EVs and the other SEC fractions were resuspended in Laemmli Sample Buffer (Bio&#x02010;Rad). Cells lysates corresponding to 4&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> &#x000a0; cells, the number of particles indicated in figures legends for EV fractions and the intermediate and soluble fractions obtained from the same volume of conditioned medium were loaded on 4%&#x02013;15% Mini&#x02010;Protean TGX Stain&#x02010;Free gels (Bio&#x02010;Rad), under non&#x02010;reducing conditions. Transferred membranes (Immuno&#x02010;Blot PVDF Bio&#x02010;Rad) were incubated with antibodies and developed using Clarity Western ECL substrate (Bio&#x02010;Rad) and the ChemiDoc Touch imager (Bio&#x02010;Rad). Antibodies for WB were anti&#x02010;human: ACE2 (clone EPR4435 against extracellular domain, Abcam 108252), TMPRSS2 (clone EPR3681 against cytoplasmic domain, Abcam 92323), ADAM10 (clone 163003, R&#x00026;D Systems MAB1427), CD63 (clone H5C6, BD Bioscience 556019), Syntenin&#x02010;1 (clone C2C3, Genetex GTX10847), CD81 (clone 5A6, Santa Cruz sc&#x02010;23692), HSP70 (clone C92F3A&#x02010;5, Enzo LifeScience, ADI&#x02010;SPA&#x02010;810&#x02010;D) and AChE (Abcam, ab31276). Secondary antibodies included HRP&#x02010;conjugated goat anti&#x02010;rabbit IgG (H+L) (Jackson 111&#x02010;035&#x02010;144), goat anti&#x02010;mouse IgG (H+L) (Jackson 111&#x02010;035&#x02010;146) and donkey anti&#x02010;goat IgG (Jackson, 705&#x02013;035&#x02010;147).</p></sec><sec id="jev212050-sec-0110"><label>4.7</label><title>Viral production</title><p>SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped lentiviruses were produced by transient transfection of 293FT cells in 150 cm<sup>2</sup> flask with 5&#x000a0;&#x003bc;g phCMV&#x02010;SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;H2, 13&#x000a0;&#x003bc;g psPAX2 and 20&#x000a0;&#x003bc;g pTRIP&#x02010;SFFV&#x02010;eGFP&#x02010;NLS and 114 ul of TransIT&#x02010;293 (Mirus Bio). SARS&#x02010;CoV&#x02010;2&#x02010;S&#x02010;pseudotyped viruses&#x02019; supernatant was centrifuged at 300xg for 5&#x000a0;min to remove dead cells, filtered with a 0.45 &#x003bc;m filter (Millipore) and loaded on top of a 20% sucrose gradient for concentration. Viral concentration was achieved by ultracentrifugation at 120,000 x <italic>g</italic> for 1 h 30&#x000a0;min at 4 &#x000b0;C in a SW32i rotor. The pellet containing concentrated SARS&#x02010;CoV&#x02010;2 S&#x02010;pseudotyped virus from three 150 cm<sup>2</sup> flasks was resuspended in 1&#x000a0;ml EV&#x02010;depleted DMEM and 100&#x000a0;&#x003bc;l aliquots were stored at &#x02010;80&#x000b0;C.</p></sec><sec id="jev212050-sec-0120"><label>4.8</label><title>Infectivity assay</title><p>20,000 Caco&#x02010;2 or Calu&#x02010;3 cells or 10,000 293FT&#x02010;ACE2 cells were seeded in a 96 well plate 6 h before infection with SARS&#x02010;CoV&#x02010;2 S&#x02010;pseudotyped virus. Infection was performed in the absence or in the presence of different amount of EVs or human recombinant ACE2 (Abcam, 151852) by spinoculation at 1200 x <italic>g</italic> for 1 h 30&#x000a0;min at 25&#x000b0;C. 48 h after infection, cells were washed, trypsinized and fixed. Infection was measured by analysing eGFP expression using a CytoFLEX LX cytometer. Data were analysed using FlowJo software.</p></sec><sec id="jev212050-sec-0130"><label>4.9</label><title>ACE2 enzyme&#x02010;linked immunosorbent assay</title><p>Quantification of the amount of human ACE2 in the different EV preparations and other SEC fractions was done using the human ACE2 ELISA kit (Abcam, ab235649) following manufacturer's instructions.</p></sec></sec><sec id="jev212050-sec-0150"><title>AUTHOR CONTRIBUTIONS</title><p>Federico Cocozza, Ester Piovesana, Nathalie N&#x000e9;vo, Xavier Lahaye performed the experiments. Federico Cocozza, Ester Piovesana, Mercedes Tkach, Lorena Martin&#x02010;Jaular, Clotilde Th&#x000e9;ry analysed the data. Lorena Martin&#x02010;Jaular, Clotilde Th&#x000e9;ry, Mercedes Tkach designed the experiments. Ester Piovesana, Federico Cocozza, Mercedes Tkach, Clotilde Th&#x000e9;ry, Lorena Martin&#x02010;Jaular wrote the paper. Xavier Lahaye, Nicolas Manel, Julian Buchrieser, Olivier Schwartz designed plasmids. Xavier Lahaye, Nicolas Manel generated cells overexpressing ACE2 and TMPRSS2 and developed the infection assay.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Supplementary Figure. Isolation and characterization of EVs containing ACE2 and TMPRSS2</bold> (A) NTA quantification of the particles produced by 10<sup>6</sup> cells contained in pools of SEC fractions for one (Caco&#x02010;2/Calu&#x02010;3) or several (293FT) independent isolations. Error bars indicate SEM. (B, C) Quantification of signals for ACE2 and TMPRSS2 in WB from Figure 1E. (B) ACE2 signal (pooled full&#x02010;length and cleaved forms) in 3&#x02013;4 independent WB. AU&#x000a0;=&#x000a0;arbitrary units after background subtraction (C) TMPRSS2 signal ration of full length (pooled 54&#x000a0;KDa + glycosylation forms) over cleaved (2 pooled forms) in 3 independent experiments. (D) Number of particles counted in each fraction of 293FT&#x02010;mock, 293FT&#x02010;ACE2 and 293FT&#x02010;ACE2&#x02010;TMPRRS2 CCM, compared with isolation of non&#x02010;conditioned depleted medium performed in parallel. Numbers of particles are normalized to the volume of medium used for each purification. (E) WB analysis of non&#x02010;conditioned depleted medium fractions isolated by SEC (material loaded on the WB was obtained from 15&#x000a0;ml initial volume of depleted medium for EV, 1.5&#x000a0;ml for intermediate and 0.75&#x000a0;ml for soluble).</p></caption><media xlink:href="JEV2-10-e12050-s001.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jev212050-sec-0140"><title>ACKNOWLEDGMENTS</title><p>This work was supported by Institut Curie, INSERM, CNRS, grants H2020&#x02010;MSCA&#x02010;ITN (722148, TRAIN&#x02010;EV), INCa (11548) and Fondation ARC (PGA1 RF20180206962) to C Th&#x000e9;ry, LABEX DCBIOL (ANR&#x02010;10&#x02010;IDEX&#x02010;0001&#x02010;02 PSL* and ANR&#x02010;11&#x02010;LABX&#x02010;0043) to C. Th&#x000e9;ry and N. Manel, LABEX VRI (ANR&#x02010;10&#x02010;LABX&#x02010;77), ANRS (France Recherche Nord &#x00026; Sud Sida&#x02010;HIV H&#x000e9;patites; ECTZ36691, ECTZ71745), Sidaction (17&#x02010;1&#x02010;AAE&#x02010;11097&#x02010;2), ANR (ANR&#x02010;19&#x02010;CE15&#x02010;0018&#x02010;01, ANR&#x02010;18&#x02010;CE92&#x02010;0022&#x02010;01), DIM1HEALTH to N Manel. N Manel thanks Mutuelle Bleue for support. We thank Eugene Diatloff for critically reading the manuscript.</p></ack><ref-list id="jev212050-bibl-0001"><title>REFERENCES</title><ref id="jev212050-bib-0012"><mixed-citation publication-type="journal" id="jev212050-cit-0012">
<string-name>
<surname>Afar</surname>, <given-names>D. E. H.</given-names>
</string-name>, <string-name>
<surname>Vivanco</surname>, <given-names>I</given-names>
</string-name>, <string-name>
<surname>Hubert</surname>, <given-names>R. S.</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>, <given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>E</given-names>
</string-name>, <string-name>
<surname>Saffran</surname>, <given-names>D. C.</given-names>
</string-name>, <string-name>
<surname>Raitano</surname>, <given-names>A. B.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Jakobovits</surname>, <given-names>A</given-names>
</string-name> et&#x000a0;al. (<year>2001</year>). <article-title>Catalytic Cleavage of the Androgen&#x02010;regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia</article-title>. <source xml:lang="en">Cancer Research</source>, <volume>59</volume>, <fpage>6015</fpage>&#x02013;<lpage>6022</lpage>.</mixed-citation></ref><ref id="jev212050-bib-0018"><mixed-citation publication-type="journal" id="jev212050-cit-0018">
<string-name>
<surname>B&#x000f6;rger</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>D. J</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>, <given-names>J. D</given-names>
</string-name>, <string-name>
<surname>Borr&#x000e0;s</surname>, <given-names>F. E</given-names>
</string-name>, <string-name>
<surname>Bussolati</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Carter</surname>, <given-names>D. R. F</given-names>
</string-name>, <string-name>
<surname>Dominici</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Falc&#x000f3;n&#x02010;P&#x000e9;rez</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Gimona</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hill</surname>, <given-names>A. F.</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>de Kleijn</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Levine</surname>, <given-names>B. L.</given-names>
</string-name>, <string-name>
<surname>Lim</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>L&#x000f6;tvall</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Mitsialis</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Mongui&#x000f3;&#x02010;Tortajada</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Muraca</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Nieuwland</surname>, <given-names>R.</given-names>
</string-name> &#x02026; <string-name>
<surname>Giebel</surname>, <given-names>B.</given-names>
</string-name> (<year>2020</year>). <article-title>International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: Considerations for potential therapeutic agents to suppress coronavirus disease&#x02010;19</article-title>. <source xml:lang="en">Cytotherapy</source>, <volume>22</volume>, <fpage>482</fpage>&#x02013;<lpage>485</lpage>
<pub-id pub-id-type="pmid">32425691</pub-id></mixed-citation></ref><ref id="jev212050-bib-0020"><mixed-citation publication-type="journal" id="jev212050-cit-0020">
<string-name>
<surname>Cerboni</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Jeremiah</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Gentili</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gehrmann</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Conrad</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Stolzenberg</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Picard</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Neven</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Amigorena</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Rieux&#x02010;Laucat</surname>, <given-names>F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Manel</surname>, <given-names>N.</given-names>
</string-name> (<year>2017</year>). <article-title>Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes</article-title>. <source xml:lang="en">Journal of Experimental Medicine</source>, <volume>214</volume>, <fpage>1769</fpage>&#x02013;<lpage>1785</lpage>
</mixed-citation></ref><ref id="jev212050-bib-0009"><mixed-citation publication-type="journal" id="jev212050-cit-0009">
<string-name>
<surname>De Carvalho</surname>, <given-names>J. V.</given-names>
</string-name>, <string-name>
<surname>De Castro</surname>, <given-names>R. O.</given-names>
</string-name>, <string-name>
<surname>Da Silva</surname>, <given-names>E Z. M.</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>, <given-names>P. P.</given-names>
</string-name>, <string-name>
<surname>Da Silva&#x02010;Janu&#x000e1;rio</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<surname>Arruda</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Jamur</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Oliver</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Aguiar</surname>, <given-names>R. S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Dasilva</surname>, <given-names>L. L. P.</given-names>
</string-name> (<year>2014</year>). <article-title>Nef Neutralizes the Ability of Exosomes from CD4+ T Cells to Act as Decoys during HIV&#x02010;1 Infection</article-title>. <source xml:lang="en">Plos One</source>, <volume>9</volume>, <elocation-id>e113691</elocation-id>
<pub-id pub-id-type="pmid">25423108</pub-id></mixed-citation></ref><ref id="jev212050-bib-0022"><mixed-citation publication-type="book" id="jev212050-cit-0022">
<string-name>
<surname>Grzelak</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Temmam</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Planchais</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Demeret</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Huon</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Guivel&#x02010;Benhassine</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Staropoli</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Chazal</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dufloo</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Planas</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Buchrieser</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Michael Rajah</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Robinot</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Porrot</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Albert</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>K.&#x02010;Y.</given-names>
</string-name>, <string-name>
<surname>Crescenzo</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Donati</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Anna</surname>, <given-names>F.</given-names>
</string-name>, &#x02026; <string-name>
<surname>van der Werf</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <article-title>SARS&#x02010;CoV&#x02010;2 serological analysis of COVID&#x02010;19 hospitalized patients, pauci&#x02010;symptomatic individuals and blood donors</article-title>. medRxiv 2020.04.21.20068858. <pub-id pub-id-type="doi">10.1101/2020.04.21.20068858</pub-id>
</mixed-citation></ref><ref id="jev212050-bib-0006"><mixed-citation publication-type="journal" id="jev212050-cit-0006">
<string-name>
<surname>Heurich</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hofmann&#x02010;Winkler</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Gierer</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Liepold</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Jahn</surname>, <given-names>O.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Pohlmann</surname>, <given-names>S.</given-names>
</string-name> (<year>2014</year>). <article-title>TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>88</volume>, <fpage>1293</fpage>&#x02013;<lpage>1307</lpage>
<pub-id pub-id-type="pmid">24227843</pub-id></mixed-citation></ref><ref id="jev212050-bib-0016"><mixed-citation publication-type="journal" id="jev212050-cit-0016">
<string-name>
<surname>Hofmann</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Pyrc</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>van der Hoek</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Geier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Berkhout</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>P&#x000f6;hlmann</surname>, <given-names>S.</given-names>
</string-name> (<year>2005</year>). <article-title>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry</article-title>. <source xml:lang="en">Proceedings of the National Academy of Sciences of the United States of America</source>, <volume>102</volume>, <fpage>7988</fpage>&#x02013;<lpage>7993</lpage>
<pub-id pub-id-type="pmid">15897467</pub-id></mixed-citation></ref><ref id="jev212050-bib-0003"><mixed-citation publication-type="journal" id="jev212050-cit-0003">
<string-name>
<surname>Hoffmann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kr&#x000fc;ger</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Herrler</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Erichsen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Schiergens</surname>, <given-names>T. S.</given-names>
</string-name>, <string-name>
<surname>Herrler</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>N.&#x02010;H.</given-names>
</string-name>, <string-name>
<surname>Nitsche</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Drosten</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>P&#x000f6;hlmann</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <article-title>SARS&#x02010;CoV&#x02010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source xml:lang="en">Cell</source>, <volume>181</volume>, <fpage>271</fpage>&#x02013;<lpage>280</lpage>.e8<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="jev212050-bib-0019"><mixed-citation publication-type="journal" id="jev212050-cit-0019">
<string-name>
<surname>Inal</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2020</year>). <article-title>Decoy ACE2&#x02010;expressing extracellular vesicles that competitively bind SARS&#x02010;CoV&#x02010;2 as a possible COVID&#x02010;19 therapy</article-title>. <source xml:lang="en">Clinical Science</source>, <volume>134</volume>, <fpage>1301</fpage>&#x02013;<lpage>1304</lpage>
<pub-id pub-id-type="pmid">32542396</pub-id></mixed-citation></ref><ref id="jev212050-bib-0005"><mixed-citation publication-type="journal" id="jev212050-cit-0005">
<string-name>
<surname>Jia</surname>, <given-names>H. P.</given-names>
</string-name>, <string-name>
<surname>Look</surname>, <given-names>D. C.</given-names>
</string-name>, <string-name>
<surname>Tan</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Hickey</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gakhar</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Chappell</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Wohlford&#x02010;Lenane</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Mccray</surname>, <given-names>P. B.</given-names>
</string-name> (<year>2009</year>). <article-title>Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia</article-title>. <source xml:lang="en">American Journal of Physiology. Lung Cellular and Molecular Physiology</source>, <volume>297</volume>, <fpage>L84</fpage>&#x02013;<lpage>L96</lpage>
<pub-id pub-id-type="pmid">19411314</pub-id></mixed-citation></ref><ref id="jev212050-bib-0010"><mixed-citation publication-type="journal" id="jev212050-cit-0010">
<string-name>
<surname>Keller</surname>, <given-names>M. D.</given-names>
</string-name>, <string-name>
<surname>Ching</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Liang</surname>, <given-names>F. X.</given-names>
</string-name>, <string-name>
<surname>Dhabaria</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Tam</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ueberheide</surname>, <given-names>B. M.</given-names>
</string-name>, <string-name>
<surname>Unutmaz</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Torres</surname>, <given-names>V. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Cadwell</surname>, <given-names>K.</given-names>
</string-name> (<year>2020</year>). <article-title>Decoy exosomes provide protection against bacterial toxins</article-title>. <source xml:lang="en">Nature</source>, <volume>579</volume>, <fpage>260</fpage>&#x02013;<lpage>264</lpage>
<pub-id pub-id-type="pmid">32132711</pub-id></mixed-citation></ref><ref id="jev212050-bib-0015"><mixed-citation publication-type="journal" id="jev212050-cit-0015">
<string-name>
<surname>Li</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Moore</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Vasilieva</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Sui</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wong</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Berne</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Somasundaran</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Luzuriaga</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Greenough</surname>, <given-names>T. C.</given-names>
</string-name>, <string-name>
<surname>Choe</surname>, <given-names>H.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Farzan</surname>, <given-names>M.</given-names>
</string-name> (<year>2003</year>). <article-title>Angiotensin&#x02010;converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source xml:lang="en">Nature</source>, <volume>426</volume>, <fpage>450</fpage>&#x02013;<lpage>454</lpage>
<pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="jev212050-bib-0013"><mixed-citation publication-type="journal" id="jev212050-cit-0013">
<string-name>
<surname>Liao</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Jaular</surname>, <given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Soueidi</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Jouve</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Muth</surname>, <given-names>D C.</given-names>
</string-name>, <string-name>
<surname>Sch&#x000f8;yen</surname>, <given-names>T. H.</given-names>
</string-name>, <string-name>
<surname>Seale</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Haughey</surname>, <given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Ostrowski</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Th&#x000e9;ry</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Witwer</surname>, <given-names>K. W.</given-names>
</string-name> (<year>2019</year>). <article-title>Acetylcholinesterase is not a generic marker of extracellular vesicles</article-title>. <source xml:lang="en">Journal of Extracellular Vesicles</source>, <volume>8</volume>, <elocation-id>1628592</elocation-id>
<pub-id pub-id-type="pmid">31303981</pub-id></mixed-citation></ref><ref id="jev212050-bib-0023"><mixed-citation publication-type="journal" id="jev212050-cit-0023">
<string-name>
<surname>Mammano</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Sodroski</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bukovsky</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>G&#x000f6;ttlinger</surname>, <given-names>H. G.</given-names>
</string-name> (<year>1995</year>). <article-title>Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>69</volume>, <fpage>3824</fpage>&#x02013;<lpage>3830</lpage>
<pub-id pub-id-type="pmid">7745730</pub-id></mixed-citation></ref><ref id="jev212050-bib-0008"><mixed-citation publication-type="journal" id="jev212050-cit-0008">
<string-name>
<surname>Mathieu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Martin&#x02010;Jaular</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Lavieu</surname>, <given-names>G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Th&#x000e9;ry</surname>, <given-names>C.</given-names>
</string-name> (<year>2019</year>). <article-title>Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell&#x02010;to&#x02010;cell communication</article-title>. <source xml:lang="en">Nature Cell Biology</source>, <volume>21</volume>, <fpage>9</fpage>&#x02013;<lpage>17</lpage>
<pub-id pub-id-type="pmid">30602770</pub-id></mixed-citation></ref><ref id="jev212050-bib-0007"><mixed-citation publication-type="journal" id="jev212050-cit-0007">
<string-name>
<surname>Monteil</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Prado</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hagelkr&#x000fc;ys</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wimmer</surname>, <given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Stahl</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Leopoldi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Garreta</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Hurtado Del Pozo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Prosper</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Romero</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Wirnsberger</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Slutsky</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Conder</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Montserrat</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Mirazimi</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Penninger</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2020</year>). <article-title>Inhibition of SARS&#x02010;CoV&#x02010;2 infections in engineered human tissues using clinical&#x02010;grade soluble human ACE2</article-title>. <source xml:lang="en">Cell</source>, <volume>181</volume>, <fpage>905</fpage>&#x02010;<lpage>913</lpage>.e7<pub-id pub-id-type="pmid">32333836</pub-id></mixed-citation></ref><ref id="jev212050-bib-0014"><mixed-citation publication-type="journal" id="jev212050-cit-0014">
<string-name>
<surname>Moore</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Dorfman</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Wong</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Kuhn</surname>, <given-names>J. H.</given-names>
</string-name>, <string-name>
<surname>Coderre</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Vasilieva</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Han</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Greenough</surname>, <given-names>T. C.</given-names>
</string-name>, <string-name>
<surname>Farzan</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Choe</surname>, <given-names>H.</given-names>
</string-name> (<year>2004</year>). <article-title>Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin&#x02010;converting enzyme 2</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>78</volume>, <fpage>10628</fpage>&#x02013;<lpage>10635</lpage>
<pub-id pub-id-type="pmid">15367630</pub-id></mixed-citation></ref><ref id="jev212050-bib-0021"><mixed-citation publication-type="journal" id="jev212050-cit-0021">
<string-name>
<surname>Raab</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gentili</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>De Belly</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Thiam</surname>, <given-names>H.&#x02010;R.</given-names>
</string-name>, <string-name>
<surname>Vargas</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Jimenez</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Lautenschlaeger</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Voituriez</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Lennon&#x02010;Dumenil</surname>, <given-names>A.&#x02010;M.</given-names>
</string-name>, <string-name>
<surname>Manel</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Piel</surname>, <given-names>M.</given-names>
</string-name> (<year>2016</year>). <article-title>ESCRT III repairs nuclear envelope ruptures during cell migration to limit DNA damage and cell death</article-title>. <source xml:lang="en">Science</source>, <volume>352</volume>, <fpage>359</fpage>&#x02013;<lpage>362</lpage>
<pub-id pub-id-type="pmid">27013426</pub-id></mixed-citation></ref><ref id="jev212050-bib-0024"><mixed-citation publication-type="journal" id="jev212050-cit-0024">
<string-name>
<surname>Van Deun</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Mestdagh</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Agostinis</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Akay</surname>, <given-names>&#x000d6;.</given-names>
</string-name>, <string-name>
<surname>Anand</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Anckaert</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>, <given-names>Z. A.</given-names>
</string-name>, <string-name>
<surname>Baetens</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Beghein</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Bertier</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Berx</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Boere</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Boukouris</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bremer</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Buschmann</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Byrd</surname>, <given-names>J. B.</given-names>
</string-name>, <string-name>
<surname>Casert</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Cmoch</surname>, <given-names>A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Hendrix</surname>, <given-names>A.</given-names>
</string-name> (<year>2017</year>). <article-title>EV&#x02010;TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research</article-title>. <source xml:lang="en">Nature Methods</source>, <volume>14</volume>, <fpage>228</fpage>&#x02013;<lpage>232</lpage>
<pub-id pub-id-type="pmid">28245209</pub-id></mixed-citation></ref><ref id="jev212050-bib-0002"><mixed-citation publication-type="journal" id="jev212050-cit-0002">
<string-name>
<surname>Walls</surname>, <given-names>A C.</given-names>
</string-name>, <string-name>
<surname>Park</surname>, <given-names>Y.&#x02010;J.</given-names>
</string-name>, <string-name>
<surname>Tortorici</surname>, <given-names>M. A</given-names>
</string-name>, <string-name>
<surname>Wall</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mcguire</surname>, <given-names>A. T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Veesler</surname>, <given-names>D.</given-names>
</string-name> (<year>2020</year>). <article-title>Structure, function, and antigenicity of the SARS&#x02010;CoV&#x02010;2 spike glycoprotein</article-title>. <source xml:lang="en">Cell</source>, <volume>181</volume>, <fpage>281</fpage>&#x02010;<lpage>292</lpage>.e6<pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="jev212050-bib-0017"><mixed-citation publication-type="journal" id="jev212050-cit-0017">
<string-name>
<surname>Wiklander</surname>, <given-names>O. P. B.</given-names>
</string-name>, <string-name>
<surname>Brennan</surname>, <given-names>M. &#x000c1;.</given-names>
</string-name>, <string-name>
<surname>L&#x000f6;tvall</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Breakefield</surname>, <given-names>X. O.</given-names>
</string-name>, &#x00026; <string-name>
<surname>El Andaloussi</surname>, <given-names>S.</given-names>
</string-name> (<year>2019</year>). <article-title>Advances in therapeutic applications of extracellular vesicles</article-title>. <source xml:lang="en">Science Translational Medicine</source>, <volume>11</volume>, <elocation-id>eaav8521</elocation-id>
<pub-id pub-id-type="pmid">31092696</pub-id></mixed-citation></ref><ref id="jev212050-bib-0001"><mixed-citation publication-type="journal" id="jev212050-cit-0001">
<string-name>
<surname>Zhou</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>X.&#x02010;L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.&#x02010;G.</given-names>
</string-name>, <string-name>
<surname>Hu</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Si</surname>, <given-names>H.&#x02010;R.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>C.&#x02010;L.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>H.&#x02010;D.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Luo</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>, <given-names>R.&#x02010;D.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>M.&#x02010;Q.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Shen</surname>, <given-names>X.&#x02010;R.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Shi</surname>, <given-names>Z.&#x02010;L.</given-names>
</string-name> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source xml:lang="en">Nature</source>, <volume>579</volume>, <fpage>270</fpage>&#x02013;<lpage>273</lpage>
<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="jev212050-bib-0004"><mixed-citation publication-type="journal" id="jev212050-cit-0004">
<string-name>
<surname>Ziegler</surname>, <given-names>C. G. K.</given-names>
</string-name>, <string-name>
<surname>Allon</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Nyquist</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Mbano</surname>, <given-names>I. M.</given-names>
</string-name>, <string-name>
<surname>Miao</surname>, <given-names>V. N.</given-names>
</string-name>, <string-name>
<surname>Tzouanas</surname>, <given-names>C. N.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yousif</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Bals</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hauser</surname>, <given-names>B. M.</given-names>
</string-name>, <string-name>
<surname>Feldman</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Muus</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Wadsworth</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<surname>Kazer</surname>, <given-names>S. W.</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>, <given-names>T. K.</given-names>
</string-name>, <string-name>
<surname>Doran</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Gatter</surname>, <given-names>G. J</given-names>
</string-name>, <string-name>
<surname>Vukovic</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Taliaferro</surname>, <given-names>F.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Zhang</surname>, <given-names>K.</given-names>
</string-name> (<year>2020</year>). <article-title>SARS&#x02010;CoV&#x02010;2 receptor ACE2 Is an interferon&#x02010;stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues</article-title>. <source xml:lang="en">Cell</source>, <volume>181</volume>, <fpage>1016</fpage>&#x02010;<lpage>1035</lpage>.e19<pub-id pub-id-type="pmid">32413319</pub-id></mixed-citation></ref><ref id="jev212050-bib-0011"><mixed-citation publication-type="journal" id="jev212050-cit-0011">
<string-name>
<surname>Zmora</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Moldenhauer</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Hofmann&#x02010;Winkler</surname>, <given-names>H.</given-names>
</string-name>, &#x00026; <string-name>
<surname>P&#x000f6;hlmann</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>). <article-title>TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells</article-title>. <source xml:lang="en">Plos One</source>, <volume>10</volume>, <elocation-id>e0138380</elocation-id>
<pub-id pub-id-type="pmid">26379044</pub-id></mixed-citation></ref></ref-list></back></article>